MA33668B1 - Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer - Google Patents

Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer

Info

Publication number
MA33668B1
MA33668B1 MA34772A MA34772A MA33668B1 MA 33668 B1 MA33668 B1 MA 33668B1 MA 34772 A MA34772 A MA 34772A MA 34772 A MA34772 A MA 34772A MA 33668 B1 MA33668 B1 MA 33668B1
Authority
MA
Morocco
Prior art keywords
antibodies
treatment
cancer
protein
chimeric antibodies
Prior art date
Application number
MA34772A
Other languages
Arabic (ar)
English (en)
Inventor
Jean-François Haeuw
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA33668B1 publication Critical patent/MA33668B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux anticorps capables de se lier spécifiquement à la protéine CD151 humaine, notamment des anticorps monoclonaux d'origine murine qui sont chimériques et humanisés. Elle concerne également les séquences d'acides aminés et les séquences nucléiques codant pour ces anticorps. L'invention comprend également l'utilisation de ces anticorps comme médicaments pour le traitement prophylactique et/ou thérapeutique de cancers et dans des procédés ou trousses de diagnostic pour des maladies associées à une surexpression de la protéine CD151. Finalement, l'invention comprend des produits et/ou compositions comprenant de tels anticorps en association avec des anticorps et/ou agents anticancéreux ou conjugués à des toxines et/ou des radioéléments, et leur utilisation dans la prévention et/ou le traitement de certains cancers.
MA34772A 2009-10-09 2012-04-13 Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer MA33668B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305964A EP2308897A1 (fr) 2009-10-09 2009-10-09 Anticorps chimères spécifiques de CD151 et leurs utilisations pour le traitement du cancer
US26602009P 2009-12-02 2009-12-02
PCT/EP2010/065085 WO2011042534A1 (fr) 2009-10-09 2010-10-08 Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer

Publications (1)

Publication Number Publication Date
MA33668B1 true MA33668B1 (fr) 2012-10-01

Family

ID=41682879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34772A MA33668B1 (fr) 2009-10-09 2012-04-13 Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer

Country Status (19)

Country Link
US (1) US20120275997A1 (fr)
EP (2) EP2308897A1 (fr)
JP (1) JP2013507114A (fr)
KR (1) KR20120094474A (fr)
CN (1) CN102597004A (fr)
AR (1) AR078572A1 (fr)
AU (1) AU2010305360A1 (fr)
BR (1) BR112012008266A2 (fr)
CA (1) CA2775634A1 (fr)
IL (1) IL219034A0 (fr)
IN (1) IN2012DN02696A (fr)
MA (1) MA33668B1 (fr)
MX (1) MX2012004059A (fr)
NZ (1) NZ599097A (fr)
RU (1) RU2012113418A (fr)
TN (1) TN2012000151A1 (fr)
TW (1) TW201118168A (fr)
WO (1) WO2011042534A1 (fr)
ZA (1) ZA201202291B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013125221A1 (ja) * 2012-02-21 2015-07-30 静岡県 抗体精製用アフィニティリガンド
CA2907606A1 (fr) * 2013-04-08 2014-10-16 Shionogi & Co., Ltd. Methode de detection du cancer du colon

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6245898B1 (en) * 1998-06-15 2001-06-12 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
CN103539857A (zh) * 2006-03-30 2014-01-29 葛兰素集团有限公司 针对β-淀粉样蛋白肽的抗体
EP3111955B1 (fr) * 2006-08-14 2019-01-23 Chugai Seiyaku Kabushiki Kaisha Diagnostic et traitement du cancer à l'aide de l'anticorps anti-démogléine-3
GB0619291D0 (en) * 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer
GB2468232B (en) * 2007-11-30 2012-10-24 Glaxo Group Ltd Antigen-bindng constructs
FR2929946B1 (fr) * 2008-04-11 2010-05-28 Pf Medicament Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer

Also Published As

Publication number Publication date
JP2013507114A (ja) 2013-03-04
EP2486057A1 (fr) 2012-08-15
WO2011042534A1 (fr) 2011-04-14
ZA201202291B (en) 2012-11-28
CN102597004A (zh) 2012-07-18
AR078572A1 (es) 2011-11-16
TN2012000151A1 (en) 2013-12-12
IL219034A0 (en) 2012-06-28
US20120275997A1 (en) 2012-11-01
TW201118168A (en) 2011-06-01
NZ599097A (en) 2014-03-28
MX2012004059A (es) 2012-05-22
IN2012DN02696A (fr) 2015-09-04
EP2308897A1 (fr) 2011-04-13
CA2775634A1 (fr) 2011-04-14
RU2012113418A (ru) 2013-11-20
BR112012008266A2 (pt) 2019-09-24
AU2010305360A1 (en) 2012-04-19
KR20120094474A (ko) 2012-08-24

Similar Documents

Publication Publication Date Title
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
LUC00053I9 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
GEP20135826B (en) Novel antibodies used to treat cancer
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
KR20170008202A (ko) 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
UA92505C2 (ru) Композиции на основе антитела против cd3
UA109633C2 (uk) Антитіло людини проти тканинного фактора
DE60028970D1 (de) An her2 bindende peptidverbindungen
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
GEP20115324B (en) Tweak binding antibodies
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
WO2005019258A3 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
Niesen et al. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
MA30163B1 (fr) Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques
WO2004024097A8 (fr) Compositions et methodes de traitement de maladies de nature immune
EA201000424A1 (ru) Антитела к il-23
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps